Medical isotope developer IsoRay Medical has entered into an international distribution agreement with Karlheinz Goehl-Medizintechnik Goehl in Germany for distribution in certain European markets of its GliaSite radiation therapy system, a U.S. Food and Drug Administration (FDA)-cleared balloon catheter device used in the treatment of various brain cancers, the company said.
GliaSite targets a specified high dose of a liquid radiation source in the areas most likely to contain cancer after brain tumor removal and is less likely to damage healthy brain tissue, according to IsoRay. It also eliminates the need for 30 to 40 follow-up external radiation treatments, the company said.
